• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

    2/25/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email

    – Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions –

    – If approved, PRGN-2012 would be the first and only available FDA-approved therapy for eligible patients with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries –

    GERMANTOWN, Md., Feb. 25, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the US Food and Drug Administration (FDA) has accepted the company's biologics license application (BLA) for PRGN-2012 (nonproprietary name: zopapogene imadenovec†), an investigational AdenoVerse® gene therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). The FDA granted priority review to the BLA and set a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2025. The FDA has indicated that they are not currently planning to hold an advisory committee meeting to discuss this application.

    Precigen Logo (PRNewsfoto/Precigen, Inc.)

    PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV 11. PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug Designation, and an accelerated approval pathway from the FDA, and Orphan Drug Designation from the European Commission.

    If approved, PRGN-2012 would be the first and only FDA-approved therapeutic for the treatment of adults with RRP. RRP is a rare, difficult-to-treat, lifelong neoplastic disease of the upper and lower respiratory tracts caused by infection with HPV 6 or HPV 11 that can be fatal. Currently, there is no cure for RRP and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity. As a result, the cycle of recurrence and surgery continues and patients can require hundreds of lifetime surgeries.1-7 The cumulative risk of laryngeal injury increases with each RRP surgery, particularly with patients requiring five or more lifetime surgeries.8 There is high unmet need for a therapeutic alternative to prevent these irreversible surgery-related injuries.

    The BLA is supported by data from the pivotal Phase 1/2 clinical study (NCT04724980), which were presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting and published in The Lancet Respiratory Medicine. The pivotal study met its primary safety and efficacy endpoints, with more than 50% of patients achieving Complete Response and more than 85% of patients experiencing a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment. PRGN-2012 was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. Primary endpoints included safety and Complete Response rate defined as the percentage of patients who require no RRP surgeries in the 12-month period after PRGN-2012 treatment completion. Key secondary endpoints included HPV-specific immune responses, extent of papilloma growth as measured by Derkay scoring, and quality of life as measured by Vocal Handicap Index-10 (VHI-10).

    "The priority review designation is a testament to the FDA's recognition of the significant unmet need for the RRP patient population. RRP patients have never had an FDA-approved therapy, relying instead on repeated surgeries to alleviate the symptoms of RRP without addressing the underlying disease," said Helen Sabzevari, PhD, President and CEO of Precigen. "Treatment with PRGN-2012 has shown significant, durable clinical benefit. We have patients treated with PRGN-2012 who have been surgery-free for more than three years now, bringing hope for an alternative to the cycle of repeated surgeries, which carry immense risk for irreversible damage and significant morbidity. We look forward to working with the FDA over the coming months during their BLA review and hope to introduce the first FDA-approved therapeutic option to the RRP patient population, estimated at more than 27,000 adults in the US, later this year." 

    AdenoVerse®

    Precigen's AdenoVerse platform utilizes a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens designed to modulate the immune system. Precigen's gorilla adenovectors, part of the AdenoVerse library, have potentially superior performance characteristics as compared to current competition. AdenoVerse gene therapies have been shown to generate high-level and durable antigen-specific T-cell immune responses as well as an ability to boost these responses via repeat administration. Superior performance characteristics and high yield manufacturing of AdenoVerse vectors leveraging UltraVector® technology allows Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.

    Precigen: Advancing Medicine with Precision™

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

    Trademarks

    Precigen, AdenoVerse, UltraVector and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, regulatory approvals, commercial launches and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:

    Steven M. Harasym

    Tel: +1 (301) 556-9850

    [email protected] 

    Media Contacts:

    Donelle M. Gregory

    [email protected] 

    Glenn Silver

    Lazar-FINN Partners

    [email protected] 

    †zopapogene imadenovec is the nonproprietary name for the investigational therapeutic known as PRGN-2012. Zopapogene imadenovec has not been approved by any health authority in any country for any indication.

    References

    1 Mounts, P et al. (1982). "Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx." Proc Natl Acad Sci U S A 79(17): 5425-5429.

    2 Smith, E et al. (1993). "Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction." Arch Otolaryngol Head Neck Surg 119(5): 554-557.

    3 Derkay, CS et al. (2008). "Recurrent respiratory papillomatosis: a review." Laryngoscope 118(7): 1236-1247.

    4 Derkay, CS et al. (2019). "Update on Recurrent Respiratory Papillomatosis." Otolaryngol Clin North Am 52(4): 669-679.

    5 Seedat, RY (2020). "Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review." Pediatric Health Med Ther 11: 39-46.

    6 Dedo, HH et al. (2001). "CO(2) laser treatment in 244 patients with respiratory papillomas." Laryngoscope 111(9): 1639-1644.

    7 Silver, RD et al. (2003). "Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis." Otolaryngol Head Neck Surg 129(6): 622-629.

    8 So, RJ et al. (2024). "Factors Associated with Iatrogenic Laryngeal Injury in Recurrent Respiratory Papillomatosis." Otolaryngol Head Neck Surg 170:1091-1098.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-precigens-bla-for-prgn-2012-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-with-pdufa-target-action-date-set-for-august-27-2025-302384347.html

    SOURCE Precigen, Inc.

    Get the next $PGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Precigen Inc.

      DEFA14A - PRECIGEN, INC. (0001356090) (Filer)

      5/16/25 4:05:03 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Precigen Inc.

      DEF 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/16/25 4:03:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Precigen Inc.

      10-Q - PRECIGEN, INC. (0001356090) (Filer)

      5/14/25 4:23:03 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Thomasian Harry Jr.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      5/27/25 7:30:44 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Lehr Donald P.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      5/27/25 7:28:51 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      5/27/25 7:26:58 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PGEN
    Financials

    Live finance-specific insights

    See more

    $PGEN
    Leadership Updates

    Live Leadership Updates

    See more

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Precigen downgraded by JP Morgan

      JP Morgan downgraded Precigen from Neutral to Underweight

      3/22/24 7:52:12 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Precigen

      JP Morgan initiated coverage of Precigen with a rating of Neutral

      5/23/23 7:32:58 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Precigen with a new price target

      Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00

      11/18/22 7:56:19 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports Full Year 2024 Financial Results and Business Updates

      FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i

      3/19/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 5:09:47 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 4:15:11 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      12/29/23 7:30:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

      GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

      12/27/24 9:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

      GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357

      8/9/24 8:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports First Quarter 2025 Financial Results and Business Updates

      PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

      5/14/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Precigen Inc.

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      8/13/24 4:05:10 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      5/3/24 8:01:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

      SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

      2/27/24 1:48:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care